Key facts

Below are highlights of our performance over the last 12 months:

February 2017

 

 

$3m milestone received following achievement of a clinical milestone from collaboration with Corvus

March 2017

 

 

New two-year oncology drug discovery collaboration on undisclosed target entered with Servier, strengthening existing partnership

April 2017

 

FDA issues CRL on CCP-07 NDA

April 2017

 

 

$2m milestone received following successful completion of drug discovery collaboration

April 2017

 

 

€2m payment received following achievement of three milestones in oncology drug discovery collaboration with Servier

August 2017

FDA issues CRL on CCP-08 NDA

April 2016

Successful completion of CCP-08 pivotal single-dose comparative bioavailability study  

April 2016

Successful completion of CCP-07 pivotal multiple-dose comparative bioavailability study

May 2016

Successfully raised £40m (before expenses) in Placing through issue of 80m new Ordinary Shares at a Placing Price of 50p per share

May 2016

Suir Pharma, sole supplier for Moxatag® placed in provisional liquidation

July 2016

€500k milestone received following achievement of new milestone in first oncology drug discovery collaboration with Servier

July 2016

Successful completion of CCP-08 pivotal multiple-dose comparative bioavailability study

Sept 2016

FDA accepted CCP-07 for full review, with PDUFA date of 20 April 2017

Dec 2016

FDA accepted CCP-08 for full review, with PDUFA date of 4 August 2017

Feb 2017

$3m milestone received following achievement of a clinical milestone from its collaboration with Corvus

Mar 2017

New two-year oncology drug discovery collaboration on undisclosed target entered with Servier, strengthening existing partnership

Latest News

AGM Statement

Vernalis plc ("Vernalis" or the "Company") provides an update ahead of its Annual General Meeting ("AGM") being held today at 10.30 am at the offices of Covington & Burling, 265 Strand, London WC2R 1BH. 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch